id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2003-E-0168-0004,FDA,FDA-2003-E-0168,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2004-07-27T04:00:00Z,2004,7,,,2025-10-27T18:58:34Z,,0,0,0900006480488d39
FDA-2003-E-0168-0003,FDA,FDA-2003-E-0168,Determination of Regulatory Review Period for Purposes of Patent Extension; XIGRIS,Notice,Determinations,2003-11-28T05:00:00Z,2003,11,2003-11-25T05:00:00Z,,2025-10-27T18:41:47Z,03-29333,0,0,0900006480488d36
FDA-2003-E-0168-0002,FDA,FDA-2003-E-0168,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2003-11-12T05:00:00Z,2003,11,,,2025-10-27T18:32:20Z,,0,0,0900006480488d33
FDA-2003-E-0168-0001,FDA,FDA-2003-E-0168,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2003-06-09T04:00:00Z,2003,6,,,2025-10-27T18:12:27Z,,0,0,0900006480488cdf